Mild Cognitive Impairment (MCI) is a condition in which patients show an objective evidence of impairment in one or more cognitive domains but a spared independence in daily functional abilities. The cognitive domain which results to be the most impaired defines the clinical subtype. Specifically, the amnestic subtype of MCI (aMCI), which is the most frequent, is characterised by deficits in episodic memory and visuospatial abilities. Current literature reports that prompt and focused rehabilitation provided early in the disease course might slow down the development of the neurodegenerative condition. The coupling between cognitive and aerobic trainings is the most incisive non-pharmacological treatment, and its effects have been demonstrated to have an impact on global cognitive functions, quality of life, aerobic capacity, and mood in the elderly with aMCI. However, the best modality for coupling aerobic and cognitive trainings (i.e., whether sequential-SEQ: aerobic training followed by cognitive training; or simultaneous-SIM: cognitive training during aerobic training) is still unknown. The aim of the present study is to determine which modality, among SEQ or SIM, is the most incisive training in patients with aMCI. Using a Randomized Controlled design, the effect of this combined aerobic-cognitive non-pharmachological training in both modalities will be evaluated on cognitive changes assessed with standard and computerized neuropsychological batteries and in functional activity during a task-based functional Magnetic Resonance Imaging (fMRI) scan.
This study will be the first one aimed at investigating the effects of a combined aerobic and cognitive training in the two different paradigms (SIM and SEQ) on cognitive functioning and brain functional MRI activity in patients with aMCI. Previous studies on aMCI patients reported that the combination of cognitive and aerobic training is more effective than the single treatments alone on both clinical and MRI outcome measures. Specifically, with the proposed training we expect to obtain ameliorative effects in terms of episodic memory, visuospatial abilities, cerebral activity and aerobic capacities, with a consequent benefit on quality of life and mood in both experimental groups; in addition, we also expect a reduction of IL-6 and TNF-alpha expression levels, and an enhancement of the BDNF. The combined aerobic-cognitive training (in SIM and SEQ modalities) will have a duration of 3 months, with 24 sessions scheduled twice a week for 70 minutes each. The first session will last 10 minutes more compared to the others in order to provide participants with all information concerning the cognitive task that they will perform during (in SIM condition) or after the aerobic training (in SEQ condition). Aerobic and cognitive exercises will be the same for both groups (SIM and SEQ) and will be characterized as follows: * Aerobic training: 30 minutes of cyclette at 40-59% heart rate reserve (HRR) or 64-76% maximum heart rate (corresponding at Rating of Perceived Exertion by Borg -BORG RPE= 12-13 -moderate intensity-).16 The cardiac frequency will be monitored by pulse oxymeter. * Cognitive training: the entire training will last for 30 minutes and will consist of two cycles of a memory task (lasting 10 minutes) and a visuospatial task (5 minutes). For the SIM condition, patient will perform the cognitive training sited on the cyclette using an adapted computer screen and a joystick. For the SEQ condition, patient will perform the cognitive training sited on a desk using a computer and a joystick. The aerobic training will be performed on a cyclette. For the cognitive training, the cognitive exercises will train two cognitive domain 1) memory and 2) visuospatial function. 1) During the mnemonic exercises, the patients will be asked to observe a screen on which different stimuli (objects) will be presented and to remember all of them. Then the subjects will be asked to recall the most of the observed objects. The number of stimuli (objects) will progressively increase in order to progressively improving the difficulty of the mnemonic training. 2) The visuospatial task will consist on the navigation in a labyrinth projected onto a screen. The subjects will have a mouse/joystick with which they will move through the labyrinth in order to find the shortest way to exit.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
55
The SIMULTANEOUS Group (SIM) will undergo15 minutes of stretching and preparatory mobilization + 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic and cognitive training, 5 minutes cool-down) + 15 minutes of mobilization and deep breathing (total: 70 minutes). Patients will perform the cognitive training sited on the cyclette using an adapted computer screen and a joystick.
The SEQUENTIAL Group (SEQ) will undergo 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic training, 5 minutes cool-down), + 30 minutes of cognitive training (total: 70 minutes). Patients will perform the cognitive training after the aerobic training, sited on a desk using a computer and a joystick.
IRCCS San Raffaele
Milan, MI, Italy
Episodic memory improvement
The primary aim of the study is to investigate episodic memory improvement (investigated with changes in the Alzheimer's Disease Assessment Scale (ADAS-cog scale), both in short- (sooner after training) and in long-term (6 months after training). ADAS-Cog scale is a useful tool which is widely employed to assess global cognitive functioning in patients with several neurodegenerative conditions including MCI. Range score is from 0 to 70. Lower scores indicate better performance.
Time frame: Baseline, month 3, month 9
Functional MRI changes
Modifications in cerebral functional activity, measured through BOLD signal, soon after training using a task-based fMRI approach.
Time frame: Baseline, month 3
Changes in submaximal aerobic/functional walking capacity
The 6-minute walking test (6MWT) measures the distance a subject walks in 6 minutes and is used to assess changes in performance capacity
Time frame: Baseline, month 3, month 9
Mood changes
Changes in mood, as measured by the Beck Depression Inventory (BDI), following treatment at both short- and long-term follow-up. BDI is a 21-item, self-administered questionnaire designed to assess the severity of respondents' depression during the weeks prior to completing the questionnaire.
Time frame: Baseline, month 3, month 9
Quality of life changes
Modifications in quality of life as measured by the 12-item Short Form Survey (SF-12) after treatment at the short- and long-term follow up. The SF-12 is a 12-questions instrument for assessing self-reported health-related quality of life.
Time frame: Baseline, month 3, month 9
Inflammatory cytokines changes
To observe a reduction in inflammatory cytokines expression levels, specifically in interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-alpha) levels, measured at the short- and long-term follow up. This biochemical effects will have a positive effect on brain-derived neurotrophic factor (BDNF).
Time frame: Baseline, month 3, month 9
Correlation between BOLD activity during task-based fMRI and after-treatment changes in cognition
Correlation between fMRI BOLD activity and changes in cognitive function in both conditions (SIM and SEQ) after treatment at short and at long-term follow up.
Time frame: month 3, month 9
Correlation between after-treatment changes in BOLD fMRI activity and cognition
Correlation between changes in BOLD activity and cognitive functioning in both conditions (SIM and SEQ) after treatment at short and at long-term follow up.
Time frame: Month 3
Correlation between biological factors and after-treatment changes in cognition
Correlation between changes in cognitive functioning and biological factors in both conditions (SIM and SEQ) after treatment at short and at long-term follow up.
Time frame: Baseline, month 3, month 9
Differences in patterns of brain activation between HC and patients
To study brain activation differences between patients and healthy subjects by comparing fMRI BOLD activity.
Time frame: Baseline
Cognitive differences between HC and patients
Baseline cognitive differences between patients and healthy subjects using the Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog scale).
Time frame: Baseline
Biological differences between HC and patients
Biological differences in BDNF, IL-6, and TNF-alpha levels between patients and healthy controls.
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.